Today: 7 February 2026
Subscribe
Browse Category

NYSE:NMR News 2 December 2025 - 26 January 2026

Macquarie Group (ASX:MQG) Stock Outlook for December 2025: Qube Bid, Nomura Deal and 2026 Forecast

Macquarie Group (ASX:MQG) Stock Outlook for December 2025: Qube Bid, Nomura Deal and 2026 Forecast

Sydney – 2 December 2025 Macquarie Group Limited (ASX:MQG), Australia’s best‑known investment bank and global infrastructure investor, enters December 2025 in the middle of a major strategic reshaping. The stock is trading around A$193–194 per share, down roughly 10–14% for the year and well below its 2025 highs above A$240, leaving it mid‑range in a 52‑week band of about A$160 to A$243.Intelligent Investor+1 At the same time, Macquarie has: Against this backdrop, analysts still see upside, but they are increasingly split between “Buy” and “Hold” as profits become more cyclical and regulatory risks accumulate. Macquarie share price in early December
2 December 2025
······

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop